Zobrazeno 1 - 10
of 19
pro vyhledávání: '"Mahanjit Konwar"'
Publikováno v:
Perspectives in Clinical Research, Vol 12, Iss 3, Pp 159-164 (2021)
Background: The approval process of every drug regulatory agency differs, and hence, the time required for the approval of a new drug varies. This results in a drug lag and India is no exception to this phenomenon. A drug lag precludes Indian patient
Externí odkaz:
https://doaj.org/article/de40117a3ad14aa2a08b245957de6f1f
Publikováno v:
Lung India, Vol 37, Iss 2, Pp 169-173 (2020)
The Global Initiative for Asthma (GINA) recently released their updated Global Strategy for Asthma Management and Prevention Guide (2019). The pocket guide for practicing clinicians states that “the 2019 GINA strategy report represents the most imp
Externí odkaz:
https://doaj.org/article/3b7e037e591e463d873e919244874f96
Publikováno v:
Perspectives in Clinical Research, Vol 9, Iss 4, Pp 179-183 (2018)
Investigator-initiated studies (IISs) help by generating data on effectiveness and safety of a drug in the real-world setting and attempt to answer questions that clinicians face in their day-to-day practice. These are studies that are initiated and
Externí odkaz:
https://doaj.org/article/53985c7bac844877b55466f0160f1d1b
Publikováno v:
Annals of Indian Psychiatry, Vol 1, Iss 2, Pp 84-87 (2017)
Valbenazine is the first drug approved by the US Food and Drug Administration for the treatment of adults with tardive dyskinesia (TD) on April 11, 2017. It acts as a reversible inhibitor of vesicular monoamine transporter 2. It is available orally w
Externí odkaz:
https://doaj.org/article/c7e548f890e444c4a0741e8e2b3bbf74
Publikováno v:
Current Reviews in Clinical and Experimental Pharmacology. 17:216-235
Introduction: Hydroxychloroquine (HCQ) has recently become the focus of attention in the current COVID-19 pandemic. With an increase in the off-label use of HCQ, concern for the safety of HCQ has been raised. We, therefore, performed this systematic
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f6174bde7b764ec25d4d59fc9871c3b5
https://doi.org/10.2174/1574884716666210726104424
https://doi.org/10.2174/1574884716666210726104424
Publikováno v:
Current Drug Safety. 17:158-167
Remdesivir is an adenosine analogue drug that targets RNA-dependent RNA polymerase enzyme and inhibits viral replication. As of 22nd October, 2020, US FDA fully approved the drug Remdesivir for the treatment of COVID-19 patients who requires hospital
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::fd4d0945e8792423e4c8aa44d5312adb
https://doi.org/10.2174/1574886316666210728110330
https://doi.org/10.2174/1574886316666210728110330
Publikováno v:
Journal of Oncology Pharmacy Practice. 29:557-576
Background Immune checkpoint inhibitors (ICIs) have changed the landscape of management of advanced cancers. It is imperative to evaluate the safety of nivolumab and ipilimumab based therapies. This study was aimed to assess the comparative safety pr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e009d68cd549247e187af26f60094699
https://doi.org/10.1177/10781552221074315
https://doi.org/10.1177/10781552221074315
Publikováno v:
Perspectives in Clinical Research.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0139b7540469860aa21c82f2e047aa69
https://doi.org/10.4103/picr.picr_137_21
https://doi.org/10.4103/picr.picr_137_21
Publikováno v:
International journal of clinical practice. 2022
Background. Liraglutide in a 3.0 mg subcutaneous dose daily is approved for weight reduction. Objectives. Objectives are to evaluate the efficacy and safety of liraglutide 3.0 mg in patients with overweight and obesity irrespective of diabetic status
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::00b192d423696fa04464df42ded9ef97
https://pubmed.ncbi.nlm.nih.gov/35936066
https://pubmed.ncbi.nlm.nih.gov/35936066
Publikováno v:
Journal of postgraduate medicine. 68(3)
Background Randomized controlled trials [RCTs] form the corner-stone of evidence-based medicine. RCTs published in high impact factor journals such as the New England Journal of Medicine [NEJM] are a key driver of clinical practice and policy decisio
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0776b18c746bd207cb2e46d156962082
https://pubmed.ncbi.nlm.nih.gov/35975345
https://pubmed.ncbi.nlm.nih.gov/35975345